Go Beyond Blood Sugars®

Change Your Tools, Not Your Workflow

Welcome, Medical Providers!

People with diabetes are living longer and healthier lives with fewer complications because of technological advances that facilitate earlier identification and interventions. Diabetes Testing Centers™ (DTC) is transforming Primary Care and Multispecialty Clinics into advanced 'Hospital-Level Care' clinics that offer comprehensive diabetes care. Our objective is to provide holistic care by integrating state-of-the-art technologies and services to address the destructive physical aspects of diabetes while emphasizing mental well-being, lifestyle factors, and personalized interventions. 

Diabetes Testing Centers™ (DTC) champions the role of medical assistants (MAs) over traditional medical providers like physicians, nurse practitioners, or physician assistants. In this approach, the medical provider demonstrates leadership by overseeing medical assistants conducting assessments. This fosters a balanced healthcare system, addressing challenges such as provider shortages and ensuring efficient management of cost, access, and quality. MAs are key to delivering efficient ancillary services to the clinic, making them essential contributors to the holistic healthcare experience.

Diabetes Testing Centers™ specialize in testing the most common diabetes-related conditions from multiple specialists, enabling clinics to offer our cutting-edge technologies that are not typically available in the average medical clinic. The tests conducted at a Diabetes Testing Center™ are eligible by insurance coverage, making them financially accessible to many individuals seeking comprehensive diabetes care. We offer different care models such as Fee-for-Service, Managed Care, and Value-Based Care.  

Join Over 800 Medical Clinics in the U.S.

Diabetes Complications

Diabetes, Prediabetes, and Insulin-Resistance

Diabetes: A Multispecialty Disease

Diabetes, is a complex and multispecialty disease that extends its influence beyond the simple realm of elevated blood glucose levels. Diabetes is known to affect all of the major organs of the human body, including the heart, kidneys, liver, and pancreas, among others. Managing diabetes is crucial to preventing these complications and maintaining overall health. Recognizing that diabetes is not solely about managing blood sugar levels, we recognize the profound interplay of these systems and their collective impact on a patient's overall health. 

Diabetes-related health conditions reflect a complicated network of interconnected health problems that may arise from the body's inability to regulate a healthy glucose level to each organ. This can cause or exacerbate other conditions, resulting in a domino effect that spreads throughout the body and leads to various health complications. Unmanaged diabetes triggers a cascade of interconnected health problems. When blood sugar levels chronically run high, it damages blood vessels throughout the body, leading to complications in organs, like those listed below:

Mitigating Morbidities and Mortalities

Evidence-Based Technologies Mitigate Diabetes-Related Conditions

Click here to see which assessments can make a meaningful impact on your practice and patient outcomes.

Exclusive Programs

Click Here to See Our Exclusive Programs.

Turnkey Premium Solutions

Diabetes Testing Centers™ stands out in the industry due to its flexibility and quick response to emerging trends and evolving patient requirements. This allows us to promptly recognize emerging healthcare trends and seamlessly integrate them into our service offerings. Our agile approach enables us to remain at the forefront of innovation, ensuring that we consistently provide advanced solutions that address the ever-changing landscape of diabetes management and related health issues. By staying responsive to current trends, we can effectively meet the dynamic needs of patients and healthcare partners, delivering timely and impactful solutions that drive positive outcomes and enhance overall patient care.

Our Exclusive Programs are comprehensive solutions are meticulously designed to meet the current healthcare needs and cater to the diverse concerns impacting individuals living with diabetes. These innovative programs not only address a range of health issues but also provide seamless reimbursement pathways for medical providers. By streamlining the reimbursement processes, our programs allow medical providers to focus on delivering exceptional care while ensuring financial stability and operational efficiency within their practices. Through our turnkey solutions, healthcare professionals can effectively manage conditions such as:

At Diabetes Testing Centers™, our mission is to enhance the well-being and quality of life of every patient under a providers care. Through our specialized programs and cutting-edge treatments, we are committed to providing personalized care that yields transformative outcomes with above average reimbursements. With ourdedication to innovation and excellence, we invite you to explore the difference that our Exclusive Programs can bring to your practice and to the lives of your patients.

Test and Therapy (avg reimbursement of $100)

Semaglutide (GLP-1) Program

Our Semaglutice (GLP-1) Program Involves Reimbursable Assessments

Semaglutide (GLP-1) Program

A Semaglutide (GLP-1) program for medical providers offers an array of robust and multifaceted resources aimed at providing comprehensive support for effectively managing type 2 diabetes and facilitating long-term weight management. Through this service, medical providers gain access to a wide range of tools, strategies, and educational materials designed to optimize patient care and treatment outcomes. These resources encompass various aspects of diabetes management and weight loss, including patient education, treatment planning, medication administration guidance, lifestyle modification strategies, monitoring and follow-up protocols, and reimbursement assistance. By leveraging these comprehensive support mechanisms, medical providers can enhance their capacity to deliver tailored, evidence-based care that addresses the unique needs and challenges of each patient, ultimately fostering improved health outcomes and quality of life. This service includes:

Overall, a Semaglutide (GLP-1) service empowers medical providers to deliver effective, personalized care for patients with type 2 diabetes and obesity, leading to improved health outcomes and enhanced quality of life.

Assessments Identify Complications

Cardiovascular Assessment

Cardiovascular diseases are the leading cause of death among people worldwide.

Cardiovascular Mortalities

Diabetic Cardiomyopathy is a disorder of the heart muscle in people with diabetes. Diabetic cardiomyopathy is a condition where diabetes adversely affects the structure and function of the heart muscle. While traditional cardiovascular diseases are often associated with conditions like high blood pressure or atherosclerosis, diabetic cardiomyopathy occurs independently of these factors. Patients with diabetes Type 2 have up to a 74% increased risk of developing Heart Failure (HF), and diabetic patients with HF are 4x more likely to die than those without HF. Importantly, unrecognized HF is highly prevalent in Type 2 diabetics, with over one quarter (27.7%) of those over 60's having previously undiagnosed HF in one report. Therefore it is one, if not the, most important assessment to be measured for all Type 2 diabetic patients and people with 2 or more comorbidities. 

Heart disease may go undiagnosed until symptoms of myocardial infarction, heart failure, or arrhythmia appear. The goal should be to prevent heart failure symptoms by screening at-risk patients for asymptomatic heart dysfunction and implementing cost-effective interventions in the early stages. Echo is the most common way to diagnose heart failure, but our CardioANS™ can provide an inexpensive early screening for all at-risk patients with a high reimbursement. Also, the cardiorenal axis is a new target for intervention in heart failure. Cardiorenal and metabolic comorbidities are common in most people with diabetes and obesity and the interdependent relationship between the heart and the kidneys is an increasingly important target for intervention in the treatment of heart failure, as addressing both organs together can lead to better outcomes for patients.

Our CardioANS test is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). The CardioANS graphs the heartbeat as it moves through systolic and diastolic cycles. It tracks deviations in fingertip pressure caused by flexible arteries and produces a tight, regular graph for stiff arteries. Using a proprietary algorithm, the device analyses arterial pulse wave variations and compares them against a large body of research to accurately assess arterial hardening. 

The Framingham Study found that individuals with asymptomatic left ventricular systolic dysfunction (LVSD) at entry had a nearly 5X increase in the risk of developing symptomatic heart failure (HF) compared to those with normal left ventricular function.

Kannel WB, Gordon T, and National Heart Institute (U.S.) (1968) The Framingham study: An epidemiological investigation of cardiovascular disease. Bethesda, MD., United States. Department of Health, Education, and Welfare, National Institutes of Health.

Long COVID-19 Consequences

Long COVID, or post-acute consequences of SARS-CoV-2 infection (PASC), can have implications for the cardiovascular system, particularly the left ventricle of the heart. While the primary respiratory symptoms of COVID-19 are well-documented, the virus's impact on the cardiovascular system can result in lingering effects that affect the left ventricle. Cardiomyopathy in COVID-19 patients refers to a condition where the heart muscle becomes inflamed and weakened due to the viral infection. COVID-19, caused by the SARS-CoV-2 virus, primarily affects the respiratory system, but it can also have significant cardiovascular implications. Cardiomyopathy in COVID-19 is one of the cardiac manifestations that can lead to severe complications. The number of hospitalizations and deaths caused by COVID-19 has reduced significantly due to the population's increasing immunity against severe disease. However, the coronavirus that causes COVID-19, SARS-CoV-2, continues to exist, and it still poses a risk to heart health, especially in people with blocked arteries, hypertension, diabetes, and other predisposing factors. Many people who have recovered from COVID-19 have reported experiencing lingering cardiovascular symptoms such as abnormal heartbeats, dizziness, and shortness of breath.

It's essential for individuals with long COVID, particularly those with cardiovascular symptoms, to be tested in the primary care setting to determine if there is should be more comprehensive imaging studies like echocardiograms to evaluate the structure and function of the left ventricle. Monitoring the left ventricle's health is crucial for developing targeted interventions and treatment plans to address the lingering cardiovascular effects of the virus.

Our CardioANScomprehensive test, facilitated by our diagnostics suite, meticulously analyzes various facets of cardiovascular health. It delves into heart rate variability and mean heart rate, providing crucial insights into the intricate dynamics of the cardiovascular system. The examination extends to evaluating arterial elasticity and peripheral arterial stiffness, offering valuable insights into vascular health. Furthermore, the test explores the aging of blood vessels and the efficiency of blood circulation, providing a comprehensive perspective on vascular aging. Additionally, it measures the impact of mental and physical stress on the cardiovascular system, furnishing valuable information on stress resilience. Lastly, the test scrutinizes autonomic nervous system function, contributing to a thorough understanding of the body's regulatory mechanisms. This multifaceted analysis ensures a holistic assessment of cardiovascular well-being.

Features of the tests:

COVID-19 survivors, regardless of infection severity, are more likely to develop cardiovascular conditions such as heart failure or coronary disease within 30 days post-infection.

Painful Neuropathy

Identify & Measure Small Nerve (A-Delta & C Fibers)

"The Device (DND) Replaces Tuning Forks and Monofilaments..."

Kazu Suzuki DPM, Medical Director of the Tower Wound Care Center at the Cedars-Sinai Medical Towers in Los Angeles, CA; Managing Neuropathy And Pain In Wound Care Patients, Podiatry Today; September 2015; 26-27.

Our Diabetic Neuropathy Device™ (DND) is the first multi-objective, non-invasive tool cleared by the FDA to identify and measure large and small nerve fibers in peripheral extremities. 

Identify & Measure Large Nerve (A-Beta Fibers)

Diabetic Neuropathy Mortalities

Diabetic Neuropathy (DN) is often overlooked as a mortality risk, emphasizing the critical importance of comprehensive assessments and early interventions to address its potential impact on overall health and well-being. It is also expected, if not an obligation, for the medical community to utilize the most modern and objective diagnostic tools in medicine, rather then relying on subjective tools such as tuning forks (invented in 1711) and monofilaments (invented in 1938). While these tools may be cost-effective, they present potential risks that could harm patients with misdiagnosis. Relying on outdated tools may result in delayed interventions and increase the rate of complications due to the possibility of false negatives and positives.  The Diabetic Neuropathy Device™ addresses the underdiagnosis and undertreatment of diabetic neuropathy by providing a modern and objective diagnostic approach. In contrast to the subjective nature of tuning forks and monofilaments, the device offers more accurate assessments, early detection, and enhances the quality of patient care

Diabetic Neuropathy Accounts for More Hospitalizations Than All Other Diabetic Complications Combined...

Aaron Vinik, MD, Ph.D., Endocrinologist, Diabetic Neuropathies, February 5, 2018

Pain has a significant impact on individuals in the United States and is more prevalent than diabetes, heart disease, and cancer. The CDC warns that the failure to diagnose both painful and painless neuropathy accurately can potentially lead to amputations of the toes, feet, or legs. While primary care providers are crucial in managing chronic pain, there is a notable gap in emphasizing the value of non-opioid alternatives among clinicians and insurance companies. Diabetic Neuropathy (DN) has two forms of peripheral neuropathy due to diabetes mellitus, which often coexist within the same diabetic patient. Around 50% of patients may experience symptomatic or painful neuropathy (small fiber), while up to 50% may exhibit asymptomatic or insensate neuropathy (large fiber). Both forms, whether painful or asymptomatic, present substantial challenges for patients, carrying morbidity and mortality risks that can significantly alter their lives.

(Painful) Small Fiber Neuropathy Can Only be Verified with Thermal Thresholds or Skin Biopsies.

Aaron Vinik, MD, Ph.D., Endocrinologist, Diabetic Neuropathies, February 5, 2018

DN remains poorly understood, as there have been few prospective studies on this condition. The main reason is the lack of standardized methodologies for the diagnosis of DN. Unlike diabetic retinopathy and nephropathy, the lack of simple, accurate, and readily reproducible methods of measuring neuropathy has been a major challenge. Furthermore, the methods currently used are not only subjective and reliant on the examiner’s interpretation but tend to diagnose DN when it’s already well established. When patients fail a monofilament test, they may have severe neuropathy, and it may be too late to intervene. The appropriate diagnosis must be objectively assessed as early as possible to manage a patient's care or be referred to the appropriate specialists. People with diabetes are living longer and healthier lives with fewer complications because of technological advances, earlier interventions, and, in some cases, all-natural supplements like Dr. A. Vinik MD PhD nerve health supplements.

(Painless) Diabetic Large Nerve Fiber Dysfunction, as Measured by Vibration, Predicts Foot Ulceration, Amputation, and Mortality.



A monofilament screening is a subjective test that evaluates sensory perception in the feet, especially in those with diabetes.


Our objective device identifies, measures, and verifies both small-fiber and large-fiber neuropathy.


'Best supplement that scientific thinking can offer for nerves,' by renowned Endocrinologist A. Vinik MD PhD.

Dementia and Diabetes

Our self-administered test can be given remotely or in-clinic. This 10-min test will show if a person is having problems with thinking, learning, and remembering. Learn more.

Digital Cognitive Assessments

At Diabetes Testing Centers™, we understand the importance of comprehensive assessments for individuals managing diabetes. There is a known correlation between being overweight, having Type 2 diabetes, and an increased risk of developing Dementia and Alzheimer's disease. Some researchers use the term Type 3 diabetes to describe the theory that dysfunction in insulin resistance and insulin-like growth factors in the brain may be a cause of Alzheimer's disease. Our latest innovation takes a unique approach – introducing our digital Cognitive Assessments, a breakthrough solution that requires no hardware, ensuring a hassle-free experience for healthcare providers and patients. 

Unlike traditional pen and paper tests, our digital Cognitive Assessments are a solution for long-term cognitive monitoring. The test takes 5-10 minutes to complete and has been clinically validated to evaluate eight aspects of cognitive function. The evaluation provides normal ranges for age and can be self-administered by the patient. It allows for in-office or remote testing, tracks longitudinal results, and is highly reimbursable by medical payers. Conducting these assessments before initiating treatment establishes a baseline for comparison and enables healthcare providers to adjust treatment plans if needed to minimize cognitive side effects.

NOTE: It is advised that medical providers evaluate a patient's cognitive status before starting medications that are known to impair memory and recall functions. This can ensure patient safety and facilitate better monitoring of any cognitive changes that may arise during treatment. These medications include psychotropics (antidepressants, antipsychotics, mood stabilizers, and anxiolytics), anticholinergics, benzodiazepines, opioids, antiepileptics, corticosteroids, cholinesterase inhibitors, and chemotherapy agents. Consult a doctor or pharmacist for personalized advice.

80% of People with Alzheimer's Have Type 2 Diabetes or Insulin Resistance 

Why a Digital Cognitive Assessment? 

Compared to the traditional pen-and-paper Montreal Cognitive Assessment (MoCA), our Cognitive Assessment has tested over half a million people to date and offers several advantages:

1. Standardization: Using digital administration can increase consistency in test presentation and results.

2. Automated Scoring: Eliminates scorer subjectivity and reduces the potential for human error in tallying results.

3. Accessibility: Can be taken remotely, increasing access for individuals who cannot travel to a clinic.

4. Efficiency: Automating the administration and scoring process saves time for administrators and patients.

5. Data Management: It is easier to store, track, and retrieve patient data for longitudinal monitoring.

6. Point-of-Care: Can provide immediate feedback and results, which can be beneficial for clinicians and patients alike.

7. Environmental Impact: Reduces the use of paper, contributing to environmentally friendly practices.

Each assessment tool has its strengths, and medical providers typically select the tool that best fits their clinical context. One patient tested can pay for an unlimited amount of tests monthly.

Take Our Free Cognitive Assessment

Diabetes-Related Video

Click here to see if any products or services are good for your practice.

Call us, before your competitors do. ;)